Ämnen: Haelso-sjukvaard

  • U.S. FDA Licenses sanofi pasteur’s ADACEL™ Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis

    First and Only Booster in the U.S. for Protection against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has licensed ADACEL™ (Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) Vaccine for protection against tetanus, d

  • SANOFI-AVENTIS JOINS THE PARIS 2012 « CLUB DES ENTREPRISES » BACKING THE PARIS BID TO HOST THE 2012 OLYMPIC AND PARALYMPIC GAMES

    Sanofi-aventis, The world’s third largest pharmaceutical group, is joining the Paris 2012 Corporate Club in support of the Paris candidature to host the 2012 Olympic and Paralympic Games. As of today, 20 major companies of international stature - Accenture, Accor, Airbus, Air France, Bouygues, Carrefour, Crédit Agricole, EDF, France Télécom, Gaz de France, Lafarge, Lagardère, LVMH, Publicis, RA

  • ANNUAL GENERAL MEETING

    The Annual General Meeting of sanofi-aventis shareholders was held on May 31, 2005. The General Meeting approved the financial statements for the year ended December 31,2004. Also approved was the distribution of a net dividend of 1.20 euro per share, a 17.6% increase over the previous year. The dividend will be paid out on June 7, 2005. The General Meeting has reappointed PricewaterhouseCoope

  • World Heart Federation och sanofi-aventis förenar sina krafter för att förebygga uppkomsten av hjärt–kärlsjukdomar

    Paris, Frankrike & Genève, Schweiz – 23 maj 2005 - World Heart Federation och sanofi-aventis tillkännagav idag att de har ingått ett treårigt partnerskapsavtal för att med förenade krafter förbättra förebyggandet och kontrollen av hjärt–kärlsjukdomar. Tillkännagivandet gjordes vid World Heart Federations sjätte internationella kongress om förebyggande kardiologi (ICPC) i Brasilien, och bekräf

  • New study results further enhances the role of Eloxatin® in early and advanced stages of colon cancer

    Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France – May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study f

  • Taxotere® regimen demonstrates significant survival benefit in the treatment of advanced gastric cancer

    Contact : Anne Bancillon 33-6-86-31-03-89 ~ Taxotere®-Based Chemotherapy Reduces Risk of Death by 23 Percent ~ – Final results from the largest international study in the reatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere® (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere®, cisplatin and 5-fluorouracil)

  • 2005 first-quarter net sales growth ahead of world pharmaceutical

    market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by re

  • “1st year results of RIO-EUROPE study published in the Lancet”.

    Press release from Professor Luc Van Gaal (University Hospital Antwerp), principal investigator of the Rio-Europe trial, entitled: “1st year results of RIO-EUROPE study published in the Lancet”. Best regards, Media Relations Department 174, avenue de France - 75013 PARIS - FRANCE - Tél. : +33 1.53.77.40.00 - Fax : +33 1.53.77.41.33 - www.sanofi-aventis.com Sanofi-aventis - Siège Social :

  • Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes

    Contact : Dr. Robert SEBBAG +33 (0)1 53 77 47 80 +33 (0)6 08 17 21 83 EMBARGO UNTIL APRIL 15, 2005 – 1:00 p.m. (CET) In his address to the closing plenary session of BioVision – the World Life Sciences Forum - Jean-François Dehecq, Chairman and CEO of sanofi-aventis, set out the guiding principles of his Group's strategy in its Policy of Access to Medicines in the "Southern Countries".

  • FDA issues approvable letter for Ambien CR™ CIV for teh treatment of insomnia

    FDA ISSUES APPROVABLE LETTER FOR AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED RELEASE) CIV FOR THE TREATMENT OF INSOMNIA Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for AMBIEN CR™ (zolpidem tartrate extended release) CIV. AMBIEN CR™ is the controlled-release formulation of zolpidem, the world’s

  • Sanofi pasteur awarded $97 million HHS contract to accelerate cell-culture pandemic influenza vaccine development

    Major U.S. public health initiative complements sanofi pasteur’s leadership in global pandemic preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health and Human Services Department (HHS) to speed the production process for new cell culture influenza vaccines in the U.S. and the design of a U.S.-based cell-cultu

  • Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the aventis acquisition financing entered into in April 2004

    Sanofi-aventis announced today the simultaneous signature of a medium-term syndicated credit agreement amounting to €8 billion and four bilateral credit facilities amounting to €500 million each. The syndicated credit agreement consists of two revolving credit lines each having a different maturity: • a €5.5 billion five-year tranche with the possibility of extending the maturity up to seven

  • RESCHEDULING OF THE PRE-TRIAL ORDER DATE IN THE UNITED STATES PLAVIX® LITIGATION

    Today sanofi-aventis announced that, at the request of sanofi-aventis, Apotex, and their respective affiliates, the U.S. District Court for the Southern District of New York has approved an extension of the date for submission by the parties of the pre-trial order in its Plavix® patent-infringement litigation with Apotex and Dr. Reddy’s Laboratories. The new date is May 13, 2005. The submission

  • Sanofi-aventis joins the fight against tuberculosis in South Africa

    in partnership with the Nelson Mandela Foundation and the South African Department of Health THE TB FREE PROGRAM for the treatment of tuberculosis sufferers In Johannesburg today, South African Health Minister Dr. Manto Tshabalala-Msimang and sanofi-aventis Chairman and CEO Jean-François Dehecq inaugurated the first training center in support for patients receiving treatment for tuberculosi

  • COURT GRANTS SANOFI-AVENTIS'S REQUEST FOR ORDER OF PROHIBITION IN THE CANADIAN PLAVIX®LITIGATION

    The Canadian Federal Court of Ottawa has granted sanofi-aventis’s application for an order of prohibition against the Minister of Health and Apotex Inc. in relation to Apotex’s 2003 application in Canada for a marketing authorization for a generic version of clopidogrel bisulfate tablets. The Canadian Court rejected Apotex's challenge to the Plavix® patent and held that the asserted claims are nov

  • FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL™ Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

    – Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend licensure of ADACEL™ (Tetanus Toxoi

  • Sanofi Pasteur seeks to broaden age group for new vaccine, Menactra™, to protect against meningococcal disease

    Submits supplemental license application Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, is seeking U.S. government approval to broaden the age indication for its new meningococcal vaccine Menactra™ (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). The company has filed a supplemental application with the U.S. Food and Drug Adminis

  • Sanofi-aventis sues Novopharm for patent infringement in Canada

    Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin. Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®. Sanofi

  • Clopidogrel improved coronary perfusion and reduced mortality in acute heart attack

    Results from two major clinical trials presented at ACC (PARIS and PRINCETON, NJ, MARCH 9, 2005) – Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute ST-segment elevation myocardial infarction (STEMI), a certain kind of heart attack. Results of the COMMIT/CCS-2 (ClOpidogrel

  • Sanofi Aventis och Pfizer seek approval to market Exubera® in the United States

    Pfizer Inc. and the sanofi-aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera® (inhaled human insulin powder). Exubera®, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for o

Visa mer
Fyll i din epostadress för att följa Sanofi

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Sanofi.

Okej